These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2381138)

  • 21. Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment.
    Cockshott ID
    Drugs; 1989; 38 Suppl 2():10-7. PubMed ID: 2575975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
    Tornio A; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
    Reyderman L; Kosoglou T; Statkevich P; Pember L; Boutros T; Maxwell SE; Affrime M; Batra V
    Int J Clin Pharmacol Ther; 2004 Sep; 42(9):512-8. PubMed ID: 15487810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of pantoprazole in man.
    Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
    Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man].
    Liu XD; Xie L; Wang J; Zhou YS; Wang Z; Liu GQ
    Yao Xue Xue Bao; 1996; 31(10):737-41. PubMed ID: 9863240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations.
    Benkö S; Drabant S; Grézal G; Urmös I; Csörgö M; Klebovich I
    Arzneimittelforschung; 1997 Aug; 47(8):913-6. PubMed ID: 9296277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
    Qandil AM; Rezigue MM; Tashtoush BM
    Eur J Pharm Sci; 2011 Jun; 43(3):99-108. PubMed ID: 21466853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system.
    Nakagawa A; Shigeta A; Iwabuchi H; Horiguchi M; Nakamura K; Takahagi H
    Biomed Chromatogr; 1991 Mar; 5(2):68-73. PubMed ID: 1868260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with atenolol in patients with chronic liver disease.
    Kirch W; Schäfer-Korting M; Mutschler E; Ohnhaus EE; Braun W
    J Clin Pharmacol; 1983 Apr; 23(4):171-7. PubMed ID: 6863581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure.
    Cayen MN; Ferdinandi ES; Hicks DR; Gonzalez R; Cosyns L; Dubuc J; Kraml M; Edwards KD
    Clin Pharmacol Ther; 1990 Jan; 47(1):50-6. PubMed ID: 2295219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.
    Andersson T; Olsson R; Regårdh CG; Skånberg I
    Clin Pharmacokinet; 1993 Jan; 24(1):71-8. PubMed ID: 8448974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
    Niemi M; Backman JT; Granfors M; Laitila J; Neuvonen M; Neuvonen PJ
    Diabetologia; 2003 Oct; 46(10):1319-23. PubMed ID: 12898007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and pharmacokinetics of cefprozil.
    Barriere SL
    Clin Infect Dis; 1992 Jun; 14 Suppl 2():S184-8; discussion S195-6. PubMed ID: 1617036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats.
    Sallustio BC; Foster DJ
    Drug Metab Dispos; 1995 Sep; 23(9):892-9. PubMed ID: 8565777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.